Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jun 7;96(6):1325–1337. doi: 10.4269/ajtmh.16-0634

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©The American Society of Tropical Medicine and Hygiene

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

Figure 5. — Seroconversion rates to dengue virus types 1–4 up to 1 year post-dose 2 (according-to-protocol cohort for immunogenicity M13). 1 μg + alum indicates participants who received 1 μg/serotype/dose adjuvanted with alum; 4 μg + alum indicates participants who received 4 μg/serotype/dose adjuvanted with alum; 1 μg + AS01_E indicates participants who received 1 μg/serotype/dose adjuvanted with AS01_E; 1 μg + AS03_B indicates participants who received 1 μg/serotype/dose adjuvanted with AS03_B. Monovalent, bivalent, trivalent, and tetravalent seropositivity rates are defined as the percentage of subjects who are seropositive to 1, 2, 3, and all 4 DENV types, respectively. No seroconversion was observed in the placebo group, which was therefore not shown. Not all numbers add up to 100% due to rounding. D56 = Day 56 (1 month post-dose 2); M7 = Month 7 (6 months post-dose 2); M13 = Month 13 (12 months post-dose 2).